Merck KGaA (OTCMKTS:MKKGY – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.14, Zacks reports. Merck KGaA had a net margin of 12.31% and a return on equity of 9.03%.
Merck KGaA Price Performance
Merck KGaA stock traded up $1.83 during midday trading on Wednesday, reaching $28.57. 84,684 shares of the stock were exchanged, compared to its average volume of 119,465. The company’s fifty day moving average is $25.99 and its 200-day moving average is $27.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.46. The firm has a market cap of $18.46 billion, a PE ratio of 12.70, a PEG ratio of 2.40 and a beta of 0.97. Merck KGaA has a 52 week low of $23.73 and a 52 week high of $31.00.
Analysts Set New Price Targets
A number of brokerages recently commented on MKKGY. Deutsche Bank Aktiengesellschaft cut shares of Merck KGaA from a “buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Sanford C. Bernstein raised shares of Merck KGaA to a “hold” rating in a report on Thursday, March 19th. Four investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold”.
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
See Also
- Five stocks we like better than Merck KGaA
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
